| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab alone | atezolizumab plus cometinib | pembrolizumab alone |
| mCRC - 1st line (L1) 1 | | | |
| mCRC - 2nd line (L2) 3 | | | |
Comparator:
vs Standard of Care (SoC); vs regorafenib;
Risk of bias:
low;
some concerns;
high;
NA;